Respiratorius (RESP) Q1 2025 earnings summary

Executive summary

• Net sales remained at 0 KSEK for Q1 2025, unchanged from the same quarter last year.

• Net loss after financial items was -2,006 KSEK, compared to -1,760 KSEK in Q1 2024.

• Positive market feedback for lead candidate VAL001, with strong clinical results and favorable safety profile.

• Strategic focus on regulatory preparations and partner discussions for VAL001 commercialization.

Financial highlights

• Net sales: 0 KSEK (Q1 2024: 0 KSEK).

• Net loss: -2,006 KSEK (Q1 2024: -1,760 KSEK).

• EPS: -0.39 SEK (Q1 2024: -0.60 SEK), calculated on 5,098,548 shares.

• Cash and cash equivalents at period end: 5,151 KSEK (Q1 2024: 748 KSEK).

• Capitalized development and patent costs: 1,887 KSEK (Q1 2024: 190 KSEK).

Outlook and guidance

• Market research indicates VAL001 could become profitable shortly after potential marketing approval, assuming successful phase III trial.

• Regulatory preparations for clinical studies are being intensified, focusing on requirements and strategies for efficient approval.

• Cautious investment climate increases demands on projects, but VAL001's strong profile seen as an opportunity.